Kodiak Sciences financials
$91.12+1.33%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$66.8M | -$59.8M | -$57.5M | -$62.4M | -$55.5M | -$59.1M | -$46.2M | -$46.6M | -$48.0M | -$46.1M | -$63.4M | -$54.5M |
| Net income | -$65.6M | -$58.2M | -$56.7M | -$61.5M | -$54.3M | -$57.5M | -$44.1M | -$43.9M | -$45.1M | -$43.0M | -$59.5M | -$50.0M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-1.05 | $-0.94 | $-1.04 | $-1.16 | $-1.03 | $-1.09 | $-0.84 | $-0.84 | $-0.86 | $-0.82 | $-1.13 | $-0.95 |
| EBITDA | -$62.7M | -$55.7M | -$52.9M | -$57.8M | -$50.9M | -$54.5M | -$41.6M | -$41.9M | -$43.3M | -$41.4M | -$63.4M | -$49.5M |
| Operating cash flow | -$46.2M | -$40.0M | -$39.4M | -$32.9M | -$34.7M | -$29.1M | -$30.1M | -$21.2M | -$26.5M | -$39.6M | -$32.2M | -$32.8M |
| Free cash flow | -$46.6M | -$41.0M | -$39.4M | -$32.9M | -$34.8M | -$29.3M | -$30.2M | -$21.4M | -$26.5M | -$39.6M | -$59.8M | -$32.9M |
| Diluted shares | 62.6M | 61.9M | 54.4M | 52.9M | 52.8M | 52.7M | 52.7M | 52.6M | 52.6M | 52.5M | 52.5M | 52.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $125.9M | $169.5M | $209.9M | $72.0M | $104.2M | $138.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $256.8M | $306.0M | $351.5M | $218.1M | $256.7M | $297.9M |
| Total liabilities | $195.7M | $193.9M | $194.2M | $194.4M | $186.4M | $189.1M |
| Shareholders' equity | $61.1M | $112.1M | $157.4M | $23.7M | $70.3M | $108.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology